STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [Form 4] MapLight Therapeutics, Inc. Insider Trading Activity

MapLight Therapeutics (MPLT) CEO sells 68,491 shares in planned trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger reported multiple open-market sales of Voting Common Stock. Across several trades on May 7–11, 2026, he sold a total of 68,491 shares, according to the transaction summary.

The sales were executed at weighted average prices within reported ranges from about $27.11 to $30.90 per share, with detailed ranges provided for each trade. A footnote states these transactions were carried out under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre-arranged rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider Kroeger Christopher A.
Role Chief Executive Officer
Sold 68,491 shs ($1.95M)
Type Security Shares Price Value
Sale Voting Common Stock 342 $27.57 $9K
Sale Voting Common Stock 877 $28.70 $25K
Sale Voting Common Stock 6,871 $30.04 $206K
Sale Voting Common Stock 5,890 $30.56 $180K
Sale Voting Common Stock 29,624 $27.48 $814K
Sale Voting Common Stock 1,582 $28.56 $45K
Sale Voting Common Stock 3,205 $29.20 $94K
Sale Voting Common Stock 14,880 $28.47 $424K
Sale Voting Common Stock 5,220 $29.15 $152K
holding Voting Common Stock -- -- --
Holdings After Transaction: Voting Common Stock — 1,525,967 shares (Direct, null); Voting Common Stock — 101,190 shares (Indirect, See footnote)
Footnotes (1)
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.8833 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $28.1099 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $29.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.12 to $29.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.3045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
Shares sold 68,491 shares Total non-derivative sales May 7–11, 2026
May 11 sale price $30.56 per share One reported open-market sale transaction
Additional May 11 price $30.04 per share Another May 11 open-market sale
Lowest reported price range $27.11–$28.1099 Weighted average range in one footnote
Highest reported price range $30.305–$30.90 Weighted average range in another footnote
Indirectly held shares 101,190 shares Held by C&M Kroeger Nominee Trust as of May 7, 2026
10b5-1 plan adoption date December 29, 2025 Date CEO adopted trading plan referenced in footnote
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
voting and dispositive power financial
"The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power."
Voting Common Stock financial
"security_title: "Voting Common Stock" in each non-derivative transaction entry"
open-market sale financial
"transaction_action: "open-market sale" and description: "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kroeger Christopher A.
(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock05/07/2026S(1)14,880D$28.47(2)1,565,940D
Voting Common Stock05/07/2026S(1)5,220D$29.15(3)1,560,720D
Voting Common Stock05/08/2026S(1)29,624D$27.48(4)1,531,096D
Voting Common Stock05/08/2026S(1)1,582D$28.56(5)1,529,514D
Voting Common Stock05/08/2026S(1)3,205D$29.2(6)1,526,309D
Voting Common Stock05/11/2026S(1)342D$27.57(7)1,525,967D
Voting Common Stock05/11/2026S(1)877D$28.7(8)1,525,090D
Voting Common Stock05/11/2026S(1)6,871D$30.04(9)1,518,219D
Voting Common Stock05/11/2026S(1)5,890D$30.56(10)1,512,329D
Voting Common Stock101,190ISee footnote(11)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.8833 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $28.1099 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $29.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.12 to $29.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.3045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
11. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
/s/ Kristopher L. Hanson, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MapLight Therapeutics (MPLT) report in this Form 4?

MapLight Therapeutics reported that CEO Christopher A. Kroeger sold 68,491 shares of Voting Common Stock. These were open-market sales spread over May 7–11, 2026, as detailed in multiple line items in the Form 4 transaction table and summary.

Over what dates did the MapLight Therapeutics (MPLT) CEO sell shares?

The CEO’s reported share sales occurred on May 7, May 8, and May 11, 2026. Each date includes several open-market sale transactions, with separate line items showing share amounts, weighted average prices, and updated share counts following each individual transaction.

How many MapLight Therapeutics (MPLT) shares did the CEO sell in total?

According to the transaction summary, Christopher A. Kroeger sold a total of 68,491 shares of Voting Common Stock. This aggregate figure reflects nine separate sale transactions reported in the non-derivative section of the Form 4 during the May 7–11, 2026 trading window.

At what prices were MapLight Therapeutics (MPLT) shares sold by the CEO?

Each Form 4 line shows a weighted average sale price, with footnotes describing price ranges. Across the trades, reported ranges span from about $27.11 to $30.90 per share, with the CEO offering to provide exact breakdowns of shares sold at each separate price.

Was the MapLight Therapeutics (MPLT) CEO’s stock sale made under a Rule 10b5-1 plan?

Yes. A footnote explains that at least one reported transaction was made under a Rule 10b5-1 trading plan adopted on December 29, 2025. Such plans pre-schedule trades, indicating that timing of these sales was arranged in advance rather than made opportunistically.

Does the Form 4 show any indirect holdings for the MapLight Therapeutics (MPLT) CEO?

Yes. One entry lists 101,190 shares of Voting Common Stock held indirectly as of May 7, 2026. A footnote states these shares are held by the C&M Kroeger Nominee Trust, where the reporting person and spouse act as co-trustees with voting and dispositive power.